PIB TrackerIndia moves to fast-track medical-device licences — by risk class
The Health Ministry has proposed amendments to the Medical Devices Rules, 2017 to shorten licensing timelines across the four risk categories — easing business while keeping the highest-risk devices under tight scrutiny.
What happened
- The Ministry of Health and Family Welfare published a draft notification proposing amendments to the Medical Devices Rules, 2017, to simplify and expedite licensing while keeping quality, safety and performance requirements intact.
- The amendments rationalise the statutory timelines for granting manufacturing licences across risk categories.
- Under the 2017 Rules, medical devices are classified into four risk-based classes — Class A (low risk), B, C and D (highest risk) — each with prescribed processing timelines.
- The proposal reduces these timelines to enable faster regulatory approvals, ease of doing business and timely availability of quality devices.
- Oversight for higher-risk devices continues, and the draft is open for public/stakeholder comments.
For Prelims
- Medical Devices Rules, 2017: Framed under the Drugs and Cosmetics Act, 1940 (medical devices are regulated as 'drugs'); administered by the CDSCO under the Drugs Controller General of India (DCGI).
- Risk-based classification: Devices are graded Class A (low, e.g. thermometers), B, C and D (high, e.g. implants, heart valves) — higher risk means stricter conditions; this risk-proportionate approach aligns with global practice (GHTF).
- Licensing authorities: State licensing authorities license lower-risk (A, B) manufacture; the Central Licensing Authority (CDSCO) handles higher-risk (C, D) and imports.
- Ease of doing business: Cutting approval timelines (without lowering standards) is a regulatory-reform/governance measure to reduce compliance burden — complementing the Jan Vishwas decriminalisation reforms.
- NMC/India's device market: India is a fast-growing medical-devices market, historically import-dependent; regulatory streamlining supports domestic manufacturing (PLI for medical devices) and availability.
- Draft notification: Publishing rules in draft for public comment (pre-legislative consultation) before final notification is standard practice.
- Don't confuse: Faster timelines ≠ weaker safety — the risk-based classification and quality/performance requirements remain; Class D (highest-risk) devices stay under central, stringent scrutiny.
For UPSC: India proposed amendments to the Medical Devices Rules, 2017 to shorten risk-based licensing timelines, easing business while preserving safety. Anchor the Medical Devices Rules under the Drugs & Cosmetics Act, CDSCO/DCGI, the four-class risk-based classification, central vs state licensing, ease-of-doing-business/regulatory reform, and PLI-driven domestic device manufacturing.
What it is NOT: Faster licensing timelines do not weaken safety — the four-class risk-based classification and quality/performance norms remain, with the highest-risk (Class D) devices under stringent central (CDSCO) scrutiny. Medical devices are regulated as 'drugs' under the Drugs & Cosmetics Act.
For Mains
Syllabus: GS2.15 · GS2.9 · Linkage L2
Anchor
Risk-proportionate, trust-based regulation — faster approvals that ease business without compromising public health.
Substantiation (data)
Draft amendments to the Medical Devices Rules, 2017 rationalise licensing timelines across the four risk classes (A–D); CDSCO/DCGI oversight retained.
Exemplification
Cite the risk-based device classification and timeline rationalisation as examples of ease-of-doing-business regulatory reform in health.
Problematisation
Balancing speed with safety/post-market surveillance, regulatory capacity (CDSCO), and import dependence remain challenges in device regulation.
Way-forward
Streamline risk-based approvals, strengthen post-market surveillance and capacity, and pair with PLI to build domestic device manufacturing.
Position
Government stance: rationalising timelines improves ease of doing business and device availability while preserving quality, safety and performance standards.
Deploys into: Health regulation & governance (Medical Devices Rules/CDSCO) · risk-based regulation & ease of doing business · domestic manufacturing (PLI) · regulatory reform (GS2.15 governance & regulatory reform, GS2.9 statutory/regulatory bodies).
Ministry of Health and Family Welfare · 2026-06-28 · PRID 2278555 · PIB source ↗